** Shares of medical software firm Omnicell OMCL.O rise 10.3% to $30.15
** OMCL expects 2025 adj. profit forecast in the range of $1.30 to $1.65 per share, compared with previously projected range of $1 to $1.65
** "The updated guidance ranges assume that the potential tariff rate on imports from China returns to 145% after the temporary 90-day reduction period," the company says
** Each 25% reduction below a 145% tariff rate, beginning August 12, represents an expected about $2 million reduction of the impact from the duties on profitability in 2025 - company
** Company expects Q2 adj profit between 24 cents and 34 cents per share vs analysts' estimates 30 cents - data compiled by LSEG
** Company also approved a $75 million stock repurchase program
** Including session's moves, stock down 33.9% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。